381 related articles for article (PubMed ID: 19818256)
1. Genetic studies of drug response and side effects in the STAR*D study, part 2.
Garriock HA; Hamilton SP
J Clin Psychiatry; 2009 Sep; 70(9):1323-5. PubMed ID: 19818256
[No Abstract] [Full Text] [Related]
2. Genetic studies of drug response and side effects in the STAR*D study, part 1.
Garriock HA; Hamilton SP
J Clin Psychiatry; 2009 Aug; 70(8):1186-7. PubMed ID: 19758527
[No Abstract] [Full Text] [Related]
3. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
[TBL] [Abstract][Full Text] [Related]
4. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of antidepressant drugs.
Horstmann S; Binder EB
Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
[TBL] [Abstract][Full Text] [Related]
6. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
Kato M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
[TBL] [Abstract][Full Text] [Related]
7. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.
Noro M; Antonijevic I; Forray C; Kasper S; Kocabas NA; Lecrubier Y; Linotte S; Mendlewicz J; Montgomery S; Snyder L; Souery D; Verbanck P; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):228-31. PubMed ID: 20453658
[TBL] [Abstract][Full Text] [Related]
8. Limitations in efficacy of antidepressant monotherapy.
Rush AJ
J Clin Psychiatry; 2007; 68 Suppl 10():8-10. PubMed ID: 17900203
[TBL] [Abstract][Full Text] [Related]
9. Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes.
Kocabas NA; Antonijevic I; Faghel C; Forray C; Kasper S; Lecrubier Y; Linotte S; Massat I; Montgomery S; Noro M; Oswald P; Snyder L; Souery D; Zohar J; Mendlewicz J
World J Biol Psychiatry; 2010 Dec; 11(8):985-90. PubMed ID: 20822372
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients.
Laje G; Allen AS; Akula N; Manji H; John Rush A; McMahon FJ
Pharmacogenet Genomics; 2009 Sep; 19(9):666-74. PubMed ID: 19724244
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Clark SL; Adkins DE; Aberg K; Hettema JM; McClay JL; Souza RP; van den Oord EJ
Psychol Med; 2012 Jun; 42(6):1151-62. PubMed ID: 22041458
[TBL] [Abstract][Full Text] [Related]
12. The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?
Hatcher S
Evid Based Ment Health; 2008 Nov; 11(4):97-9. PubMed ID: 18952951
[No Abstract] [Full Text] [Related]
13. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
[TBL] [Abstract][Full Text] [Related]
14. Variation in GNB3 predicts response and adverse reactions to antidepressants.
Keers R; Bonvicini C; Scassellati C; Uher R; Placentino A; Giovannini C; Rietschel M; Henigsberg N; Kozel D; Mors O; Maier W; Hauser J; Souery D; Mendlewicz J; Schmäl C; Zobel A; Larsen ER; Szczepankiewicz A; Kovacic Z; Elkin A; Craig I; McGuffin P; Farmer AE; Aitchison KJ; Gennarelli M
J Psychopharmacol; 2011 Jul; 25(7):867-74. PubMed ID: 20826553
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
Laje G; Perlis RH; Rush AJ; McMahon FJ
Psychiatr Serv; 2009 Nov; 60(11):1446-57. PubMed ID: 19880459
[TBL] [Abstract][Full Text] [Related]
16. HTR2A gene variation is involved in antidepressant treatment response.
Lucae S; Ising M; Horstmann S; Baune BT; Arolt V; Müller-Myhsok B; Holsboer F; Domschke K
Eur Neuropsychopharmacol; 2010 Jan; 20(1):65-8. PubMed ID: 19758789
[TBL] [Abstract][Full Text] [Related]
17. Recent molecular genetic studies and methodological issues in suicide research.
Tsai SJ; Hong CJ; Liou YJ
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):809-17. PubMed ID: 20977922
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.
Adkins DE; Clark SL; Åberg K; Hettema JM; Bukszár J; McClay JL; Souza RP; van den Oord EJ
Transl Psychiatry; 2012 Jul; 2(7):e129. PubMed ID: 22760553
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics with antidepressants in the STAR*D study.
Lin E; Chen PS
Pharmacogenomics; 2008 Jul; 9(7):935-46. PubMed ID: 18597655
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant treatment practice in the face of STAR*D and STEP-BD.
Cassidy F
Bipolar Disord; 2008 Dec; 10(8):973-4. PubMed ID: 19594512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
